Coronavirus Update: Sanofi And GSK’s Vaccine Suffers Setback

Plus: Pfizer On Track In US, But Needs More Time In India

While the new mRNA-based vaccines grow closer to market, Sanofi and GSK's more established approach experiences a serious setback.US authorization in sight for Pfizer/BioNTech after positive advisory committee vote. Pfizer Seeks More Time For EUA Presentation In India.  

Sanofi - GSK
The companies believe the vaccine could be authorized and ready for use by Q4 2021, approximately a six month delay to previous timelines.

Sanofi and GlaxoSmithKline have announced a delay to their COVID-19 vaccine candidate after Phase I/II results showed it produced a disappointingly low immune response.

The companies are combining Sanofi’s recombinant protein-based vaccine with GSK’s adjuvant technology, and had hoped to move into a Phase...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip